Dr Frank Cuttitta, senior investigator and head of the Angiogenesis Core Facility at the US National Cancer Institute (NCI) based in Bethesda, Maryland, discovered in 2004 that a small protein called PAMP was a vital factor in angiogenesis, the process of forming new blood vessels that supply nutrients and oxygen to growing tumours.
The said collaboration will be performed under a Cooperative Research and Development Agreement (CRADA) where EvoGenix will provide tailored antibodies against PAMP and scientists at the NCI will carry out testing and initial clinical evaluation of these new anti-cancer therapeutics.
Read the full press release (a pdf file).
Comment Preview